Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.
about
Enzyme replacement and substrate reduction therapy for Gaucher diseaseHematopoietic stem cell transplantation for Gaucher diseaseHematopoietic stem cell transplantation for Gaucher diseaseImiglucerase in the treatment of Gaucher disease: a history and perspectiveClinical manifestations and management of Gaucher diseaseEliglustat tartrate for the treatment of adults with type 1 Gaucher diseaseIndividualization of long-term enzyme replacement therapy for Gaucher disease.Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.An overview on bone manifestations in Gaucher disease.Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.Vertebral fractures in Gaucher disease type I: data from the French "Observatoire" on Gaucher disease (FROG).Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease.Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.Therapeutic approaches for lysosomal storage diseasesGlucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage.Gaucher disease and its treatment options.Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.Gaucher disease: pathological mechanisms and modern management.Bone turnover markers in patients with type 1 Gaucher disease.Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study.Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.Gaucher disease and bone manifestations.Management of bone disease in Gaucher disease type 1: clinical practice.Hematopoietic stem cell transplantation for Gaucher disease.Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Gaucher disease
P2860
Q24187121-77AE504F-3EE5-474E-BA5C-1BEC7C08DBD1Q24202044-5BE13B0C-B9CF-475E-A57F-8259E0F25591Q24241166-BB07C1E3-F121-4F42-9656-565697010203Q24631426-8432572D-82F4-4A86-934D-D51E274D40EDQ26775747-E5A7B566-D310-429D-AFC4-16C7D0AA31E5Q26783393-55EB7EAC-4D0C-4310-A750-F41602F1CD11Q33365037-57DBCC41-5369-4A77-B3F7-ECBBB9FAAA43Q33391428-C6E86521-A41B-44ED-88F6-8033832F379BQ33393590-46CED2C0-CCE3-40BE-BB08-D28365AA1970Q33588593-4839DB2C-BF0F-49B2-8DA3-F01D7066899CQ33648876-0CB31D24-94FE-4A00-BE5F-FB5A9F5EB796Q33659850-A5BCA12F-1BBD-4FB6-9328-194D52E57ED1Q34311272-F5CC479F-3D16-40D2-9981-3C26BE502CBDQ34311420-79F01E5B-6D3C-4666-8995-906C6A02D626Q34320470-A9118F09-8324-431F-ADBD-681FFADABF1FQ34386658-1C2AA63C-CEBC-4849-BE07-F91D8A6FDF4FQ34482254-DF818BFF-8B54-4820-9A6F-BE3D956B3540Q34556549-3BA9FBF1-C7A8-4E9E-A6D6-0D23CAE18867Q36562916-2CFD1AAE-12FC-4BAF-8B5D-E4420A2B0C4CQ36737076-7B01EBDE-2F5C-4D4F-9E9C-4EAAEA21E47EQ37221766-7DF15E83-D560-44CF-A251-5678EF47A8BAQ37354438-56ACB037-568F-4C2E-A6B0-772D08DBF20AQ38265941-2581BBFB-9F05-49A6-9996-F71874BB27E3Q38290826-7D1C26E9-8DAD-4FBA-BA7F-7C1CFA029B1BQ47770048-65C0343A-ED09-42DA-81A4-B761EAFB7E95Q50155671-CF6AC0F9-9BFD-4301-8842-E9FEF6532CA6Q53128627-885828B2-E204-4DD0-B2C6-008455059FE1Q56338451-928E2C01-9248-49B9-A2B9-723EF94487CA
P2860
Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Gaucher disease: alendronate d ...... ults receiving enzyme therapy.
@ast
Gaucher disease: alendronate d ...... ults receiving enzyme therapy.
@en
type
label
Gaucher disease: alendronate d ...... ults receiving enzyme therapy.
@ast
Gaucher disease: alendronate d ...... ults receiving enzyme therapy.
@en
prefLabel
Gaucher disease: alendronate d ...... ults receiving enzyme therapy.
@ast
Gaucher disease: alendronate d ...... ults receiving enzyme therapy.
@en
P2093
P1433
P1476
Gaucher disease: alendronate d ...... ults receiving enzyme therapy.
@en
P2093
Alan E Oestreich
Gregory A Grabowski
Jay Moskovitz
Laurie Bailey
Richard J Wenstrup
Shumei Sun
P304
P356
10.1182/BLOOD-2003-11-3854
P407
P577
2004-03-09T00:00:00Z